Nog Mouse Model
Nog Mouse Model - Related Videos
00:10
Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
0 Views •
Cited by 7 •
2019
This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. Dual reconstituted immunodeficient mice achieved via intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells are susceptible to human immunodeficiency virus-1 infection and recapitulate liver damage as observed in HIV-infected patients.
03:24
Establishing Experimental Metastases Mouse Model: Implanting GFP Expressing CRC Organoid Cells in PDX Model to Detect Micrometastases
0 Views •
2023
This video describes the protocol for generating metastases by the PDX derived CRC organoids labeled with GFP lentivirus into the spleen of an immunodeficient mouse. Cancer micrometastases colonizing other organs can be detected using a fluorescence microscope to assess the GFP expression.
02:57
Spontaneous Metastasis Mouse Models: A Platform to Study the Metastatic Potential of Orthotopically Injected Colorectal Cancer Cells
0 Views •
2023
This video describes the protocol to establish a spontaneous metastasis mouse model of colorectal cancer patient-derived xenografts or PDXs. These xenograft models partially mimic the features of human carcinomas and understand the critical aspects of human malignancies, including invasion and metastasis.
08:15
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
0 Views •
Cited by 6 •
2020
We have developed a protocol for the generation and evaluation of a humanized and human immunodeficiency virus-infected NOG mouse model based on stem cell transplant, intravaginal human immunodeficiency virus exposure, and droplet digital PCR RNA quantification.
06:24
Mouse Models of Periventricular Leukomalacia
0 Views •
Cited by 28 •
2010
We established mouse models of periventricular leukomalacia (PVL), the predominant brain injury in premature infants characterized by periventricular white matter lesions. Hypoxia/ischemia with/without systemic infection are the primary causes of PVL. Unilateral carotid ligation and hypoxia exposure with/without lipopolysaccharide injection creates PVL-like lesions in P6 mice.
FAQs
Engraftment is promoted by the combined loss of functional T and B cells and the severe impairment of natural killer cell activity. These immune deficiencies reduce the host’s ability to recognize and eliminate human tumor material. As a result, implanted human cells or tumor fragments can persist in vivo with limited immune rejection, supporting development of experimental tumor models.
NOG mice cannot signal effectively through the common gamma-chain cytokine receptor, adding a major immune deficiency to their lack of functional T and B cells. This disrupted signaling further limits immune responses against human material. The resulting environment helps researchers study human tumor behavior in a living mouse rather than only in cultured cells.
A xenograft study uses human tumor cells introduced into the mouse, whereas a patient-derived xenograft uses tumor fragments obtained from a patient. Both approaches rely on the mouse’s limited immune rejection, but they represent different experimental starting materials. Together, they allow cancer researchers to examine tumor growth and treatment responses using complementary model designs.
The model supports observation of human tumors after they establish in vivo, enabling researchers to follow tumor growth and investigate metastasis. Because the tumor develops within a living organism, experiments can assess disease behavior in an animal context rather than relying solely on cell-based observations. This makes the model useful for evaluating how tumors respond over time.
Researchers introduce human tumor cells or patient-derived tumor fragments into NOG mice and use the animals to establish xenograft or patient-derived xenograft models. Once a model is established, investigators can evaluate tumor growth and metastasis and compare treatment effects. The approach connects human tumor material with measurements made in a living experimental system.
NOG-based tumor models can be used to assess anticancer drugs, immunotherapies, and combination treatments. Researchers can examine how these interventions affect tumor growth or other model outcomes, including metastasis when that feature is being studied. Using the same in vivo framework for different treatment categories supports comparative investigation of therapeutic strategies in cancer research.